SCHEMBL16410309

SCHEMBL16410309

CC(C)(C)OC(=O)Cc1ccccc1NC(=O)c1cc(Cl)cc(Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 1/20 0.40
▸ SUCNR1 Q9BXA5 5/20 0.39
▸ CFD P00746 2/20 0.39
▸ MTNR1A P48039 1/20 0.37
▸ MTNR1B P49286 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ NHERF1 O14745 1/20 0.36
▸ ACACB O00763 1/20 0.36
▸ ACACA Q13085 1/20 0.36
▸ USP2 O75604 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TTR P02766 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ TBXA2R P21731 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396288 0.82 SUCNR1 (0.55) NR1H4SUCNR1CFDTTRCYP2C9
SCHEMBL16410204 0.81 CFD (0.47) SUCNR1CFDACACBACACACYP2C9
SCHEMBL16410300 0.80 KMT2A (0.56) NR1H4KMT2AMEN1NPC1ALDH1A1
SCHEMBL16410377 0.79 NR1H4 (0.45) NR1H4SUCNR1CFDKMT2AMEN1
SCHEMBL28151972 0.77 MTNR1A (0.45) NR1H4CFDMTNR1AMTNR1BKMT2A
SCHEMBL16410459 0.76 NR1H4 (0.39) NR1H4CFDKMT2AMEN1THRB
SCHEMBL16397584 0.74 NR1H4 (0.49) NR1H4SUCNR1CFDMTNR1AMTNR1B
SCHEMBL16410489 0.74 CFD (0.41) NR1H4SUCNR1CFDALDH1A1
SCHEMBL16396793 0.74 CFD (0.50) SUCNR1CFDKMT2AMEN1THRB
SCHEMBL17764496 0.73 CFD (0.55) SUCNR1CFDACACBACACACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB NR1H4 901/4885SUCNR1 4670/4885CFD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback